Aortic Stenosis & Amyloidosis Registry

Dual pathology of significant aortic valve stenosis (AS) and cardiac amyloid deposition (CA) has been increasingly recognized as a common diagnosis in elderly patients undergoing transcatheter aortic valve replacement (TAVR) with reported prevalences of 10-15%. TAVR appears to improve outcomes of patients with AS-Amyloidosis, and should not be a reason for TAVR to be withheld in patients with a dual pathology of AS-Amyloidosis. 

There are significant gaps in understanding of pathophysiological mechanisms, disease interaction, choice of intervention, post-intervention pharmacotherapies, and outcomes. Multicenter collaborative registry data is required to fill this gap.

Aims

In patients with a dual pathology of Aortic Stenosis and Cardiac Amyloidosis, we aim to define:  
- Stages of disease severity
- Diagnostic and treatment pathways 
- Clinical outcomes